Molecular profiling establishes genetic features predictive of the efficacy of the p110β inhibitor KIN-193

Aberrant activation of the PI3K pathway is a common alteration in human cancers. Therapeutic intervention targeting the PI3K pathway has achieved limited success due to the intricate balance of its different components and isoforms. Here, we systematically investigated the genomic and transcriptomic signatures associated with response to KIN-193, a compound specifically targeting the p110β isoform. By integrating genomic, transcriptomic, and drug response profiles from the GDSC database, we identified mutational and transcriptomic signatures associated with KIN193 and further created statistical models to predict the treatment effect of KIN-193 in cell lines which may eventually be clinically valuable. These predictions were validated by analysis of the external CCLE data set. These results may assist precise therapeutic intervention targeting the PI3K pathway.